ReleaseWire Connect

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced it has awarded a $250.000 Transformational Grant in Science Education to the Biotechnology Center to support the expansion of the Center's educational training facility for science teachers. The grant is part of the Genocore Biotech Foundation's new Transformational Grants in Science Education initiative.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody, today announced that the company has appointed HonWen Long, M.D., to its Scientific Advisory Board. Dr. Wen Long is a preeminent researcher with expertise in device-based research for Neuropsychiatric Disorders. Currently Dr. Wen Long is Professor of Psychiatry, Neurology & Medicine.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs) and Fc-fusion protein drugs, today announced an agreement for the further development of a novel, oral small molecule inhibitor of Vascular Protein 1, a cell molecule that may be effective in the treatment of inflammatory diseases. The inhibitor is currently in phase II clinical development.

Genocore Biotech (ISIN:CN1000007515), an innovation-driven biopharmaceutical company focused on development and commercialization of therapeutic monoclonal antibody (mAbs), today announced that they plan to advance the companies' Hemophilia B therapy a registrational clinical trial in hemophilia B patients. The decision to advance the program is based on promising data from a pharmacokinetic study in severe, previously-treated hemophilia B patients. In addition, the therapy demonstrated a prolonged half-life compared to historical data for existing therapies, supporting advancement of the program.